Physician profile
Khadija E Mayet
NPI 1528049665
$7,523.35
in general payments reported to CMS, 2019-2025
43 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,246 · 2020: $696 · 2021: $1,134 · 2022: $1,124 · 2023: $752 · 2024: $1,026 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $934.55 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $898.64 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $815.68 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $590.61 | 2019-2025 | |
| Astellas Pharma US INC | $533.63 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $404.75 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $393.98 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $388.95 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $361.26 | 2019-2025 | |
| Abbvie INC. | $334.56 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $186.87 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $178.43 | 2022-2025 | Jynarque, Rexulti |
| Amarin Pharma, INC. | $150.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $126.31 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $123.34 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khadija Mayet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.